Table 2

Treatment details, correlative analysis, and patient outcome

No.Age (years)Prior diseaseWBC*Cytogenetics/FISHMolecularMarrow blasts*No. of prior therapiesDisease statusKIR ligand mismatchPB donor chimerism at day 7Donor PB NK cells at day 14 (cells/μL)PB percentage of Tregs at day 14Disease response at day 28Time to death/time of survival (mo)Survival status
166MDS82t(1;3),del 5q-EGFR96%2PIFNo95%123900.02%CRi1.1Dead
259MDS0.2Complex, del 7p-EGFR34%3PIFNo95%4840.1%PD0.9Dead
349RAEB-255NormalFlt3 ITD49%3PIFNo13%071%CR10Dead
451ET/MDS10del 5q-, del 20q-EGR140%3PIFNoQNS049%PD0.8Dead
55Primary AML110t(9;11)MLL95%5PIFYes0%027%PD1.1Dead
651Primary AML32Monosomy 7EVI181%4PIFYes34%241.1%PD2.5Dead
771MDS0.2Complex, del20q-MYBL26%3RelapseYes68%017%CR9.4Alive
864MPD53Monosomy 7EGFR9%5PIFNo92%5320.06%CRi2.6Dead
957MPD0.7NormalJak2 +, Flt3 ITD24%2PIFYesQNSNo11%CRi12Alive
1037Primary AML2.2NormalFlt3 ITD10%3PIFNo33%No28%CRp12Alive
1113MDS225Trisomy 6Flt3 ITD7%3PIFNo42%No10%CR10.2Dead
1254Primary AML5.6t(12;14)ETV636%4RelapseYes0%NoNAPD0.4Dead
135Primary AMLNAt(9;11)MLL33%4RelapseYes0%No16%PD1.1Dead
1416Primary AML50t(3;22) del 9qn/a85%6PIFYes99%14700%PD1.2Dead
1573Primary AML2.5Trisomy 1PBX124%2RelapseYes70%No20%CRp12Alive
  • ET, essential thrombocythemia; MPD, myeloproliferative disorder; NA, not available; PD, progressive disease; PIF, primary induction failure; QNS, quantity not sufficient; RAEB, refractory anemia with excess blasts; WBC, white blood cell.

  • * At time of therapy (in 106 cells/μL).

  • Includes prior demethylation agent.

  • Subsequent allogeneic donor stem cell transplant.